MedTrace Logo

Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia

NCT04540926 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-09-07

No results posted yet for this study

Summary

Methods: Single-center pilot study included PCR+ SARS-CoV2-patients, hospitalized from April to May 2020 in Puebla, Mexico. Comparative treatment with steroids plus CsA or steroids. Mild, moderate or severe pneumonia was measured by clinical, laboratory tests, lung damage score by computed tomography, and score for clinical improvement. Death rate was evaluated at 28 days.

Conditions

  • COVID 19 Pneumonia

Interventions

DRUG

Cyclosporin A

COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.

Sponsors & Collaborators

  • Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

    lead OTHER_GOV

Principal Investigators

  • JOSE LUIS J GALVEZ-ROMERO, MD · Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04540926 on ClinicalTrials.gov